Planned Solutions Inc. Acquires New Shares in Thermo Fisher Scientific Inc. (NYSE:TMO)

Planned Solutions Inc. purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 567 shares of the medical research company’s stock, valued at approximately $301,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Halpern Financial Inc. grew its holdings in shares of Thermo Fisher Scientific by 307.7% during the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock worth $27,000 after purchasing an additional 40 shares in the last quarter. Coppell Advisory Solutions LLC bought a new position in Thermo Fisher Scientific during the second quarter worth about $33,000. Live Oak Investment Partners bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $36,000. Tyler Stone Wealth Management acquired a new position in Thermo Fisher Scientific in the second quarter valued at about $37,000. Finally, Indiana Trust & Investment Management CO bought a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $38,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research analyst reports. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Citigroup started coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Robert W. Baird restated an “outperform” rating and issued a $670.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. Finally, Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $599.00.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $579.37 on Thursday. The firm has a market capitalization of $220.92 billion, a PE ratio of 37.50, a PEG ratio of 2.39 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The company’s 50-day moving average is $564.32 and its 200-day moving average is $519.80. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same period last year, the firm posted $5.40 EPS. The firm’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be paid a dividend of $0.39 per share. The ex-dividend date is Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.